Neurogene (NGNE) Stock: Buy, Sell, or Hold?
NGNE - Neurogene, Inc. Common Stock
$24.28
-1.80 (-6.90%)
âŧ
5d:
+1.38%
30d:
-21.5%
90d:
-30.43%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 12, 2026
19d
Get Alerted When NGNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: NGNE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: NGNE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: NGNE is currently trading at $24.28, which is considered slightly low relative to its 30-day fair value range of $24.01 to $31.69.
Technical Outlook: Technically, NGNE is in a downtrend. Immediate support is located at $21.05, while resistance sits at $29.63. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: NGNE scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $77.88 (+220.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NGNE is in a downtrend. Immediate support is located at $21.05, while resistance sits at $29.63. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: NGNE scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $77.88 (+220.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$24.01 -
$31.69
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
91.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 220.7% below Wall St target ($77.88)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.01 -
$31.69
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
Âą$3.00
(12.3%)
Support & Resistance Levels
Support Level
$21.05
Resistance Level
$29.63
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.24
Wall Street Target
$77.88
(+220.7%)
Share & Embed Analysis
Last updated: October 23, 2026 7:42 AM ET
Data refreshes hourly during market hours. Next update: 8:42 AM
Data refreshes hourly during market hours. Next update: 8:42 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NGNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 60 HOLD |
